ACRV Stock Price History and Quote Analysis: Insights for Investors
Acrivon Therapeutics, Inc. Common Stock
Stock Price Today
Acrivon Therapeutics, Inc. Common Stock (ACRV) stock surged +1.74%, trading at $7.01 on NASDAQ, up from the previous close of $6.89. The stock opened at $6.91, fluctuating between $6.85 and $7.17 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
Company Information
| Employees | 58 |
| Beta | 1.7012562 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Acrivon Therapeutics, Inc. Common Stock (NASDAQ: ACRV) stock price is $7.01 in the last trading session. During the trading session, ACRV stock reached the peak price of $7.17 while $6.85 was the lowest point it dropped to. The percentage change in ACRV stock occurred in the recent session was 1.74% while the dollar amount for the price change in ACRV stock was $0.12.
The NASDAQ listed ACRV is part of Biotechnology industry that operates in the broader Healthcare sector. Acrivon Therapeutics, Inc. Common Stock designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Ms. Katharine Peterson CPA
Vice President of Fin. & Accounting
Ms. Kristina Masson Ph.D.
Co-Founder, Executive Vice President of Bus. Operations, Treasurer, Sec. & Director
Dr. Adam D. Levy M.B.A., Ph.D.
Senior Vice President and Head of Investor Relations & Corporation Affairs
Ms. Crystal Mercado
Global Head of HR
Mr. Bruce Close
Vice President of Quality & Compliance
Dr. Eric J. Devroe Ph.D.
Chief Operating Officer
Mr. Rasmus Holm-Jorgensen
Chief Financial Officer
Ms. Mary-Alice Miller J.D.
Gen. Counsel
Mr. Joon Jung Ph.D.
Vice President & Head of Data Science
Mr. Erick Gamelin M.D., Ph.D.
Chief Medical Officer
Dr. Jesper V. Olsen Ph.D.
Academic Co-Founder, Head of Phosphoproteomics & Member of Scientific Advisory Board
Dr. Peter Blume-Jensen M.D., Ph.D.
Co-Founder, Chairman, Chief Executive Officer, Pres & Acting Chief Scientific Officer
Ms. Parvin Miah
Vice President & Head of HR
Ms. Kristina Masson M.B.A., Ph.D.
Co-Founder, Executive Vice President of Bus. Operations, Site Head, Treasurer, Sec. & Director
ACRV's closing price is 119.75% higher than its 52-week low of $3.19 where as its distance from 52-week high of $11.90 is -41.09%.
Number of ACRV employees currently stands at 58.
Official Website of ACRV is: https://www.acrivon.com
ACRV could be contacted at phone 617 207 8979 and can also be accessed through its website. ACRV operates from 480 Arsenal Way, Watertown, MA 02472, United States.
ACRV stock volume for the day was 111.8K shares. The average number of ACRV shares traded daily for last 3 months was 94.02K.
The market value of ACRV currently stands at $217.11M with its latest stock price at $7.01 and 30.97M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com